Safety and tolerability of aclidinium administered intravenously and absolute bioavailability of inhaled aclidinium in healthy male participants

Journal of Clinical Pharmacology

Volumn 52, Issue 6, 2012, Pages 819-827

  Ortiz, Stephan ^a   Flach, Stephen ^b   Caracta, Cynthia ^a   Gil, Esther Garcia ^c   Jansat, Josep M ^c  

^a FOREST RESEARCH INSTITUTE   (United States)

^b 206 Carnegie Center   (United States)

^c Almirall SA ^*  (Spain)

Author keywords

Aclidinium bromide; bioavailability; COPD; pharmacodynamics; pharmacokinetics

Indexed keywords

ACLIDINIUM BROMIDE; DRUG METABOLITE;

ADULT; APPLICATION SITE IRRITATION; APPLICATION SITE RASH; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONSTIPATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; HUMAN; HUMAN EXPERIMENT; INJECTION SITE IRRITATION; INJECTION SITE PAIN; MALE; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PLASMA CLEARANCE; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; XEROSTOMIA;

ADMINISTRATION, INHALATION; ADULT; BIOLOGICAL AVAILABILITY; BIOTRANSFORMATION; BLOOD; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; HALF-LIFE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SINGLE-BLIND METHOD; TROPANES; URINE; YOUNG ADULT;

EID: 84861830005     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270011406281     Document Type: Article

References (17)

1. Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet. 2007 ; 370: 765-773
2. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006 ; 3: e442
3. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004 ; 23: 932-946
4. Roffel AF, Elzinga CR, Zaagsma J. Muscarinic M3 receptors mediate contraction of human central and peripheral airway smooth muscle. Pulm Pharmacol. 1990 ; 3: 47-51
5. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007 ; 176: 532-555
6. Kesten S, Celli B, Decramer M, Leimer I, Tashkin D. Tiotropium HandiHaler in the treatment of COPD: a safety review. Int J Chron Obstruct Pulmon Dis. 2009 ; 4: 397-409
7. Gavalda A, Miralpeix M, Ramos I, et al. Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile. J Pharmacol Exp Ther. 2009 ; 331: 740-751
8. Alberti JJ, Martinet A, Sentellas S, Salva M. Identification of the human enzymes responsible for the enzymatic hydrolysis of aclidinium bromide. Drug Metab Dispos. 2010 ; 38: 1202-1210
9. Prat M, Fernandez D, Buil MA, et al. Discovery of novel quaternary ammonium derivatives of (3R)-quinuclidinol esters as potent and long-acting muscarinic antagonists with potential for minimal systemic exposure after inhaled administration: identification of (3R)-3-{[Hydroxy(di-2-thienyl)acetyl] oxy}-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane bromide (aclidinium bromide). J Med Chem. 2009 ; 52: 5076-5092
10. Sentellas S, Ramos I, Alberti J, et al. Aclidinium bromide, a new, long-acting, inhaled muscarinic antagonist: in vitro plasma inactivation and pharmacological activity of its main metabolites. Eur J Pharm Sci. 2010 ; 39: 283-290
11. Jansat JM, Lamarca R, de Miquel G, Schrodter A, Miletzki B, Gurniak M. Safety and pharmacokinetics of multiple doses of aclidinium bromide, a novel long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease, in healthy participants. J Clin Pharmacol. 2010 ; 49: 1239-1246
12. Jansat JM, Lamarca R, Garcia Gil E, Ferrer P. Safety and pharmacokinetics of single doses of aclidinium bromide, a novel long-acting, inhaled antimuscarinic, in healthy subjects. Int J Clin Pharmacol Ther. 2009 ; 47: 460-468
13. Joos GF, Schelfhout VJ, Pauwels RA, et al. Bronchodilatory effects of aclidinium bromide, a long-acting muscarinic antagonist, in COPD patients. Respir Med. 2010 ; 104: 865-872
14. Chanez P, Burge PS, Dahl R, et al. Aclidinium bromide provides long-acting bronchodilation in patients with COPD. Pulm Pharmacol Ther. 2010 ; 23: 15-21
15. Flach S, Jansat J, Ho J, Garcia Gil E, Caracta C, Ortiz S. Metabolism and excretion of aclidinium bromide following intravenous administration of [14C]aclidinium bromide in healthy subjects. Am J Respir Crit Care Med. 2010 ; 181: A4463
16. Schmid K, Pascual S, Garcia Gil E, Ortiz S, Jansat JM. Pharmacokinetics and safety of aclidinium bromide, a muscarinic antagonist, in adults with normal or impaired renal function: a phase I, open-label, single-dose clinical trial. Clin Ther. 2010 ; 32: 1798-1812
17. Turck D, Weber W, Sigmund R, et al. Pharmacokinetics of intravenous, single-dose tiotropium in subjects with different degrees of renal impairment. J Clin Pharmacol. 2004 ; 44: 163-172